Edition:
United Kingdom

Endocyte Inc (ECYT.OQ)

ECYT.OQ on NASDAQ Stock Exchange Global Select Market

16.79USD
6:54pm BST
Change (% chg)

$-0.54 (-3.12%)
Prev Close
$17.33
Open
$17.26
Day's High
$17.34
Day's Low
$16.58
Volume
121,563
Avg. Vol
447,347
52-wk High
$17.69
52-wk Low
$1.17

Latest Key Developments (Source: Significant Developments)

Endocyte And ITM Announce Long-Term Supply Agreement For No-Carrier-Added Lutetium-177
Monday, 9 Jul 2018 

July 9 (Reuters) - Endocyte Inc ::ENDOCYTE AND ITM ANNOUNCE LONG-TERM SUPPLY AGREEMENT FOR NO-CARRIER-ADDED LUTETIUM-177.ENDOCYTE - ADDITIONAL TERMS OF THE AGREEMENT ARE NOT DISCLOSED.ENDOCYTE - ITG WILL PROVIDE ENDOCYTE WITH 100% OF LUTETIUM-177 REQUIRED FOR THE PHASE 3 VISION TRIAL.ENDOCYTE - CO WILL PAY €5 MILLION UP-FRONT TO SUPPORT EXPANSION OF MANUFACTURING CAPACITY FOR LUTETIUM-177.  Full Article

‍Partner Fund Management LP reports a 6.6 pct passive stake in Endocyte as of Nov 6
Thursday, 16 Nov 2017 

Nov 16 (Reuters) - Endocyte Inc :‍Partner Fund Management LP reports a 6.6 percent passive stake in Endocyte Inc as of November 6 - SEC Filing​.  Full Article

Endocyte Q3 loss per share $0.55
Monday, 6 Nov 2017 

Nov 6 (Reuters) - Endocyte Inc :Endocyte reports third quarter financial results.Q3 loss per share $0.55.  Full Article

Endocyte Inc files for mixed shelf of upto $150 million
Thursday, 12 Oct 2017 

Oct 12 (Reuters) - Endocyte Inc ::Endocyte Inc files for mixed shelf of upto $150 million .Endocyte Inc says in addition, selling stockholders may offer and sell, up to 5.3 million shares of co's common stock‍​.  Full Article

Peter Dodwell reports 7.1 pct passive stake in Endocyte Inc
Thursday, 12 Oct 2017 

Oct 12 (Reuters) - Endocyte Inc :Peter Dodwell reports 7.1 percent passive stake in Endocyte Inc ‍​as of September 29 - SEC filing.  Full Article

Endocyte reports Q2 loss per share $0.33
Thursday, 4 Aug 2016 

Endocyte Inc : Q2 loss per share $0.33 . Q2 earnings per share view $-0.26 -- Thomson Reuters I/B/E/S . Endocyte reports second quarter 2016 financial results .Company revised guidance for its expected cash balance at end of 2016 to be above $130 million.  Full Article

BRIEF-Endocyte Reports Q1 Loss Per Share $0.16

* Q1 EARNINGS PER SHARE VIEW $-0.19 -- THOMSON REUTERS I/B/E/S